Norges Bank’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-357,346
| Closed | -$34.7M | – | 2115 |
|
|
2019
Q3 | $34.7M | Buy |
357,346
+10,721
| +3% | +$1.07M | 0.01% | 1102 |
|
|
2019
Q2 | $35.5M | Buy |
346,625
+35,000
| +11% | +$3.78M | 0.01% | 1112 |
|
|
2019
Q1 | $35.5M | Buy |
311,625
+124,877
| +67% | +$9.18M | 0.01% | 1095 |
|
|
2018
Q4 | $7.31M | Hold |
186,748
| – | – | ﹤0.01% | 1833 |
|
|
2018
Q3 | $10.2M | Hold |
186,748
| – | – | ﹤0.01% | 1817 |
|
|
2018
Q2 | $15.5M | Buy |
186,748
+12,347
| +7% | +$953K | 0.01% | 1651 |
|
|
2018
Q1 | $11.6M | Hold |
174,401
| – | – | ﹤0.01% | 1696 |
|
|
2017
Q4 | $8.97M | Hold |
174,401
| – | – | ﹤0.01% | 1776 |
|
|
2017
Q3 | $15.6M | Hold |
174,401
| – | – | 0.01% | 1573 |
|
|
2017
Q2 | $10.4M | Sell |
174,401
-25,318
| -13% | -$1.41M | ﹤0.01% | 1725 |
|
|
2017
Q1 | $10.7M | Buy |
199,719
+34,759
| +21% | +$2.06M | ﹤0.01% | 1713 |
|
|
2016
Q4 | $8.23M | Hold |
164,960
| – | – | ﹤0.01% | 1759 |
|
|
2016
Q3 | $9.46M | Buy |
164,960
+42,370
| +35% | +$2.44M | ﹤0.01% | 1679 |
|
|
2016
Q2 | $6.27M | Buy |
122,590
+48,731
| +66% | +$2.08M | ﹤0.01% | 1805 |
|
|
2016
Q1 | $2.18M | Sell |
73,859
-33,156
| -31% | -$1.05M | ﹤0.01% | 1985 |
|
|
2015
Q4 | $4.85M | Buy |
107,015
+90,185
| +536% | +$4.73M | ﹤0.01% | 1874 |
|
|
2015
Q3 | $702K | Buy |
+16,830
| New | +$878K | ﹤0.01% | 2158 |
|
Norges Bank's ONCE Position: Q4 2019 in Review
Norges Bank sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 357,346 shares — an estimated $34.7M sold.
Norges Bank first reported a position in ONCE in Q3 2015 and held it in 17 quarters. The position peaked at $35.5M in Q2 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.
- Norges Bank reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- Norges Bank sold 357,346 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $34.7M.
- Norges Bank first reported a position in Spark Therapeutics, Inc. Common Stock in Q3 2015 and held it in 17 quarters.
- Norges Bank's Spark Therapeutics, Inc. Common Stock position peaked at $35.5M in Q2 2019.
- 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.
Based on Norges Bank's 13F filing for Q4 2019, filed 12 Feb 2020.